Your browser doesn't support javascript.
loading
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain, Nitin; Thompson, Philip; Burger, Jan; Ferrajoli, Alessandra; Takahashi, Koichi; Estrov, Zeev; Borthakur, Gautam; Bose, Prithviraj; Kadia, Tapan; Pemmaraju, Naveen; Sasaki, Koji; Konopleva, Marina; Jabbour, Elias; Garg, Naveen; Wang, Xuemei; Kanagal-Shamanna, Rashmi; Patel, Keyur; Wang, Wei; Jorgensen, Jeffrey; Wang, Sa; Lopez, Wanda; Ayala, Ana; Plunkett, William; Gandhi, Varsha; Kantarjian, Hagop; O'Brien, Susan; Keating, Michael; Wierda, William G.
Afiliação
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thompson P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burger J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bose P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Garg N; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lopez W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ayala A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Plunkett W; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gandhi V; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • O'Brien S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Keating M; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA.
  • Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 35(12): 3421-3429, 2021 12.
Article em En | MEDLINE | ID: mdl-34007049
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Região Variável de Imunoglobulina / Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Cadeias Pesadas de Imunoglobulinas / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Região Variável de Imunoglobulina / Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Cadeias Pesadas de Imunoglobulinas / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido